Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota
Open Access
- 1 July 2016
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (7) , 4244-4251
Abstract
Solithromycin is a new fluoroketolide. The purpose of the present study was to investigate the effect of orally administered solithromycin on the human oropharyngeal and intestinal microbiota. Thirteen healthy volunteers (median age, 27.3 years) received oral solithromycin at 800 mg on day 1 followed by 400 mg daily on days 2 to 7. Fecal and saliva samples were collected at baseline and on days 2, 5, 7, 9, 14, and 21 for pharmacokinetic and microbiological analyses. Plasma samples were collected predose on days 2, 5, and 7 as proof of exposure, and solithromycin concentration ranges were 21.9 to 258 ng/ml, 18.0 to 386 ng/ml, and 16.9 to 417 ng/ml, respectively. The solithromycin concentrations in feces were 15.8 to 65.4 mg/kg, 24.5 to 82.7 mg/kg, 21.4 to 82.7 mg/kg, 12.1 to 72.4 mg/kg, 0.2 to 25.6 mg/kg, and 0 to 0.5 mg/kg on days 2, 5, 7, 9, 14, and 21, respectively. The numbers of enterobacteria and enterococci decreased and were normalized on day 14. The numbers of lactobacilli and bifidobacteria decreased from day 2 to day 14 and were normalized on day 21. The clostridia decreased on days 2, 7, and 14 and were normalized on day 21. No Clostridium difficile strains or toxins were detected during the study period. The number of Bacteroides strains was not significantly changed. The solithromycin concentrations in saliva were 0 to 1.2 mg/liter, 0 to 0.5 mg/liter, 0 to 0.5 mg/liter, and 0 to 0.1 mg/liter on days 2, 5, 7, and 9, respectively. The numbers of streptococci decreased on day 2 and were normalized on day 5. The numbers of lactobacilli, prevotellae, fusobacteria, and leptotrichiae decreased from day 2 and were normalized on day 21.Keywords
This publication has 16 references indexed in Scilit:
- The role of solithromycin in the management of bacterial community-acquired pneumoniaExpert Review of Anti-infective Therapy, 2016
- A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated GonorrheaClinical Infectious Diseases, 2015
- Randomized, Double-Blind, Multicenter Phase 2 Study Comparing the Efficacy and Safety of Oral Solithromycin (CEM-101) to Those of Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial PneumoniaAntimicrobial Agents and Chemotherapy, 2013
- In Vitro Activity of the New Fluoroketolide Solithromycin (CEM-101) against a Large Collection of Clinical Neisseria gonorrhoeae Isolates and International Reference Strains, Including Those with High-Level Antimicrobial Resistance: Potential Treatment Option for Gonorrhea?Antimicrobial Agents and Chemotherapy, 2012
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile InfectionAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microfloraJournal of Antimicrobial Chemotherapy, 2000
- Impact of Moxifloxacin versus Clarithromycin on Normal Oropharyngeal MicrofloraEuropean Journal of Clinical Microbiology & Infectious Diseases, 2000
- Comparative Effects of Moxifloxacin and Clarithromycin on the Normal Intestinal MicrofloraScandinavian Journal of Infectious Diseases, 2000
- Impact of dirithromycin on the normal oral and intestinal microfloraEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Effect of erythromycin and clindamycin on the indigenous human anaerobic flora and new colonization of the gastrointestinal tractEuropean Journal of Clinical Microbiology & Infectious Diseases, 1982